METASTATIC CANCER

This study tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can help men with advanced prostate cancer that no longer responds to hormone therapy. About 60 participants will receive either one or two DNA vaccines plus pembrolizumab for up to t…

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people with metastatic cancer that has started to grow again. About 69 adults with cancers such as melanoma, lung, bladder, kidney, or head/neck cancer will re…

This study tests whether adding ramucirumab to the standard drug osimertinib can delay cancer growth in people with advanced EGFR-mutant non-small cell lung cancer. About 160 participants who have not had prior targeted therapy will be randomly assigned to receive either the comb…

This early-stage study tests a new treatment for people with advanced colorectal or other cancers that make a protein called CEA. The treatment, Ac225-DOTA-M5A, is an antibody that seeks out CEA on cancer cells and delivers a radioactive payload to kill them. The main goals are t…

This study looks at whether giving focused, high-dose radiation (SABR) to a small number of growing cancer spots can help people with advanced lung cancer stay stable longer. About 90 adults with non-small cell lung cancer that has spread and is growing in just a few places will …

This study tests a drug called adagrasib (MRTX849) in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 731 participants with various cancers (e.g.,…

This study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop advanced pancreatic cancer. It involves 3 newly diagnosed adults with inoperable or metastatic pancreatic cancer. The goal is to se…

This study tests a new approach for people with cancer that has spread to the bone. Participants receive a precise, high-dose radiation treatment (SBRT) followed by surgery within one week to stabilize the bone. The goal is to see if this combination is safe and helps prevent the…

This study tests whether adding two experimental drugs (avutometinib and defactinib) to standard chemotherapy can help people with advanced pancreatic cancer that has spread. About 40 adults with untreated metastatic pancreatic cancer will take part. The goal is to see if the com…

This study tests two different doses of the targeted drug adagrasib in 200 adults with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants have already tried chemotherapy and immunotherapy. The goal is to see which dose works bett…

This study tests whether adding a new drug (CGT9486) to standard sunitinib helps people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib. About 442 adults with inoperable or spreading GIST will receive either the combo or sunitinib alone. Th…

This study enrolls healthy relatives of patients with advanced HPV16-related cancer. Donors receive a therapeutic HPV vaccine to boost their immune cells against the virus. Their blood cells are then used for a bone marrow transplant or immune cell infusion in the cancer patient.…

This study tests a combination of three drugs (pemetrexed, etrumadenant, and zimberelimab) in 10 adults with advanced bladder cancer that has a specific genetic change called MTAP deficiency. All participants had prior immunotherapy. The goal is to see if the combo shrinks tumors…

This study tests the safety of combining the drug RP-3500 with palliative radiation therapy in people whose metastatic solid tumors have a specific change in the ATM gene. About 49 adults with advanced cancer will receive the combination to find the highest dose with few side eff…

This early-phase study tests a new drug (RP-6306) combined with two standard chemotherapies for people with recurrent ovarian or uterine cancer that has a specific gene change (TP53 mutation). The main goals are to find the safest dose and see if the combination can shrink tumors…

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or central nervous system (CNS). The goal is to see if the drug can shrink or control these brain tumors. Participants must have mild or no symptoms from their brain metastases and not need incr…

This phase 2 trial tests the drug avelumab in 25 people with advanced penile cancer who cannot have standard platinum chemo or whose cancer worsened after it. Avelumab works by blocking a protein called PD-L1, which may help shrink or stop tumor growth. The main goal is to see ho…

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. About 20 adults with various CEA-positive cancers will receive the injection and have scans over two days. The goal is to see if this method can dete…

This study tests whether an 8-week digital health program called COBRA is safe and practical for older adults with cancer. The program focuses on balance and resistance exercises to help maintain strength and mobility. Researchers will track how many participants stick with the p…

This study looks at whether involving a radiation specialist early in care can improve quality of life for people with metastatic cancer. About 156 adults with cancer that has spread will be split into two groups: one gets standard care plus early radiation oncology input, the ot…

This study tests a program that helps cancer patients and their caregivers manage difficult emotions and communicate better about the illness. It includes a version tailored for Latinx participants. The goal is to reduce distress, improve quality of life, and help families discus…

This study is trying to find blood markers that could warn doctors ahead of time if a cancer patient will have serious side effects from immunotherapy drugs. About 69 adults with advanced solid tumors are being followed to see if certain inflammatory or autoimmune markers in thei…

This study looks at tumor and blood samples from 180 people with metastatic cancer who have been treated with the drug trastuzumab deruxtecan (T-DXd). The goal is to find a specific genetic marker (ERBB2 mRNA level) that can predict how well a patient will respond to the drug. No…

This study aimed to review past cases of patients with a rare liver cancer (intrahepatic cholangiocarcinoma) who were treated with tiny radioactive beads called radiospheres. The goal was to understand how well the treatment worked and what risks were involved. However, the study…

This study collects white blood cells and tumor cells from up to 7,000 cancer patients and healthy volunteers. The cells are used in the lab to grow large numbers of immune cells that may be given back to patients in future experimental treatments. No direct treatment is provided…

This study looks at whether analyzing the genes of a tumor (from a tissue sample or a blood draw) can help doctors pick a more effective treatment for people with advanced solid cancers that have stopped responding to standard therapies. About 235 participants will have their tum…

This study looks at how certain cancers (head and neck, esophagus, and anal) change at the genetic and immune level when treated with chemotherapy or immunotherapy. About 39 adults with advanced cancer will provide blood and tumor samples before and during treatment. The goal is …